IMPACT
We want to positively impact the lives of more than 500,000 people with cancer around the world by 2030.
Unique combination studies across our pipeline
Active oncology partnerships
Indication approvals we have potential to deliver by 2030
Cancer steals possibility. We're taking it back.™
- Trigger tumor-intrinsic cell death
- Promote immune-mediated tumor killing
- Remodel the tumor-permissive microenvironment
Trigger tumor-intrinsic cell death
Promote immune-mediated tumor killing
Remodel the tumor-permissive microenvironment
We’re purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugates and small molecules to cell therapy-based approaches, we're creating new possibilities for people with cancer.
Explore Our PipelineThe Promise of Cell Therapy at Kite
Kite, a Gilead Company, is changing the way cancer is treated with cell therapy. Kite's cell therapies use the power of a patient’s own immune system to target and attack their cancer cells.
Learn More About KiteClinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We currently offer more than 25 therapies in the United States and are rapidly growing our portfolio through internal research and development and external collaborations.
Progress
We're transforming how cancer is treated by collaborating with partners from across the entire oncology community, including advocates, patients, industry and academia.
Partnerships play a key role in our growing pipeline and capabilities. Through approximately 40 active alliances and collaborations, we’re joining forces with some of the most promising oncology companies to access external sources of innovation, pursue next-generation cancer therapies and expand potential indications in our pipeline.
Latest News
Some of the content on this page is not intended for users outside the U.S.